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Abstract Intramuscular teicoplanin (400 mg every 12 h
for three doses, then 400 mg daily, intramuscularly) was
prescribed for a 37-year-old woman with presumptive
diagnosis of cellulitis. On the 14th day of treatment, she
developed generalized maculopapular rash, accompanied
by fever, wheezing, shortening of breath, and lym-
phadenopathy. Lab tests revealed abnormal liver enzymes,
leukocytosis, and eosinophilia. The treatment was inter-
rupted with suspicion of drug reaction. Fever subsided after
48 h. Skin eruption and respiratory symptoms began to
resolve within 2 weeks. The follow-up lab tests performed
1 month later indicated resolution of liver dysfunction.
With respect to delayed onset of symptoms including fever,
generalized rash, lymphadenopathy, and organ involve-
ment, drug reaction with eosinophilia and systemic symp-
toms (DRESS) was highly suspected. The causality was
evaluated by conventional scoring systems. The reaction
was rated as probable (score = 5) according to RegiSCAR
and possible (score = 5) based on Kardaun et al.’s scoring
system. However, DRESS was not confirmed by the
Japanese group’s criteria for diagnosis of DRESS/drug-
induced hypersensitivity syndrome (DIHS).
Key Points
Drug reaction with eosinophilia and systemic
symptoms (DRESS) is a life-threatening reaction
that necessitates determination and discontinuation
of the offending drug.
The aromatic structure of teicoplanin is shared by
most other medications involved in DRESS.
The use of additional treatment including
intravenous immunoglobulins, corticosteroids and
antivirals is generally based on experience rather
than proven benefits drawn from well-designed
clinical trials.
Introduction
Drug reaction with eosinophilia and systemic symptoms
(DRESS) syndrome is defined as an idiosyncratic, rare, and
life-threatening reaction. The clinical features of the syn-
drome, including fever, rash, facial edema, lym-
phadenopathy, hematological abnormality, and internal
organ involvement, arise 10–30 days following drug
exposure. This late onset of symptoms discriminates
DRESS from some other drug-induced skin reactions such
as erythema morbilliform [1, 2]. The most common sus-
pected medicines causing DRESS include aromatic anti-
convulsants (carbamazepine, phenytoin, phenobarbital, and
lamotrigine), allopurinol, and antibiotics (sulfasalazine,
vancomycin, and minocycline) [2]. To the best of our
knowledge, there are limited reports of teicoplanin-induced
DRESS in the literature [2–6]. Here, we report a case of
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DRESS associated with teicoplanin. This report is impor-
tant to enhance our knowledge on severe side effects of
teicoplanin.
Case Report
A 37-year-old woman was admitted to hospital with red-
ness and edema of inguinal area. The involved area was
tender and warm on examination. With a presumptive
diagnosis of cellulitis, vancomycin 1 g twice daily was
prescribed. After 24 h, due to the acceptable clinical state
of the patient, treatment was planned to be completed in the
ambulatory setting. Vancomycin was replaced with teico-
planin, considering its ease of administration as an intra-
muscular injection (400 mg every 12 h for three doses,
then 400 mg daily).
On the 14th day of treatment, the patient developed
generalized maculopapular rash (Fig. 1), accompanied by
fever (39 C), wheezing, shortening of breath, and cer-
vical and axillary lymphadenopathy. Lab tests revealed
abnormal liver enzymes [alanine aminotransferase (ALT)
134 IU/L, aspartate transaminase (AST) 141 IU/L, alka-
line phosphatase (ALP) 345 IU/L], leukocytosis (white
blood cell count 17,000/lL) with eosinophilia to more
than 8% (1360/lL), a blood urea nitrogen (BUN) value of
24 mg/dL, and a serum creatinine (SCr) value of 0.8 mg/
dL. The treatment was interrupted with suspicion of drug
reaction. After 48 h, the patient defervesced. Skin erup-
tion and respiratory symptoms began to resolve within
2 weeks. The follow-up lab test performed 1 month later
indicated resolution of liver dysfunction (ALT 22 U/L,
AST 18 U/L).
Discussion
With respect to diversity in scoring systems and differential
diagnoses, the exact incidence of DRESS, as a life-threat-
ening skin reaction, remains unknown. This could be par-
tially because there is no gold-standard test for diagnosis of
DRESS, and as a result, the diagnosis remains a challenge
and is mainly based on conventional proposed scoring
systems. The most common scoring systems to stratify
DRESS are RegiSCAR [7], the Japanese group’s criteria
for diagnosis of DRESS/drug-induced hypersensitivity
syndrome (DIHS) [8], and a system proposed by Kardaun
et al. [9] (Table 1).
DRESS is classified as a type IV drug-induced hyper-
sensitivity reaction that is characterized by delayed onset of
symptoms. The rising of eosinophil count and non-necro-
tizing lesions differentiate DRESS from other type IV
drug-induced hypersensitivity reactions such as Stevens-
Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).
In regard to delayed onset of signs and symptoms including
skin rash (more than 50% of body surface area), fever
(more than 38.5 C), and enlarged lymph node (more than
1 cm in two sites), DRESS was highly suspected. These
findings are in concordance with previous reports of tei-
coplanin-induced DRESS [3, 4, 6]. Additional work-up was
performed to evaluate hematological abnormalities and
organ involvement, which revealed leukocytosis with
eosinophilia and liver involvement.
It is noticeable that the patient work-up remained
incomplete. Chest x-ray or computerized tomography (CT)
scan and skin biopsy were not performed due to patient
non-compliance. Therefore, pulmonary involvement was
judged only on the basis of clinical symptoms. The
Fig. 1 Generalized
maculopapular rash on the neck
and trunk
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association of viral reactivation with DRESS has been
reported in previous publications [10]. Testing for human
herpesvirus-6, human herpesvirus-7, and Epstein-Barr
virus antibodies was not requested because of limited
resources. In general, our presumptive diagnosis was
mainly based on clinical signs and symptoms and acces-
sible lab tests.
On the basis of the scoring systems mentioned above,
the reaction was rated as probable (score = 4) according to
RegiSCAR and possible (score = 5) according to Kardaun
et al.’s scoring system. Since presence of atypical lym-
phocytes and reactivation of human herpesvirus were not
investigated, DRESS was not confirmed by the Japanese
group’s criteria for diagnosis of DRESS/DIHS.
Regardless of the aforementioned limitations, the clini-
cal picture was in favor of DRESS.
Anticonvulsants with aromatic structure are the most
common agents associated with DRESS. The aromatic
structure of vancomycin and teicoplanin may explain the
occurrence of DRESS with these agents [2].
In this case, teicoplanin was used instead of vancomycin
according to the Summary of Product Characteristics
(available at http://www.sanofi.com.au). Given the similar
structure of vancomycin and teicoplanin, cross-reactivity is
anticipated. Therefore, vancomycin may have prompted
the reaction with teicoplanin. Resolution of symptoms after
discontinuation of teicoplanin highlights it as the causative
agent.
Withdrawal of the offending medication and supportive
care are the mainstay of management. The implementation
of additional treatment including intravenous
immunoglobulins, corticosteroids and antivirals is gener-
ally based on experience rather than proven benefits drawn
from well-designed clinical trials [11–13]. Administration
of corticosteroids in severe pulmonary involvement seems
to be reasonable according to results from some studies
[13, 14]. However, we did not implement these interven-
tions, considering the lack of proven benefit and the
patient’s overall state of health. Furthermore, without
performing imaging tests, pulmonary involvement could
not be confirmed.
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